WO2025131019 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE)
National phase entry is expected:
Publication Number
WO/2025/131019
Publication Date
26.06.2025
International Application No.
PCT/CN2024/140813
International Filing Date
20.12.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE)
[French]
COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DE LA SOUS-UNITÉ BÊTA E DE L'INHIBINE (INHBE)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2023/140636
21.12.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4343 | |
| EPO | Filing, Examination, Granting | 66157 | |
| Japan | Filing, Examination, Granting | 4068 | |
| South Korea | Filing, Examination, Granting | 6097 | |
| USA | Filing, Examination, Granting | 19390 |
Total:
100,055
Contact Us
Abstract[English]
Compositions and methods useful to reduce expression of INHBE gene and for treatment of INHBE-associated diseases and conditions are provided. Provided are INHBE dsRNA agents, INHBE antisense polynucleotide agents, compositions comprising INHBE dsRNA agents, and compositions comprising INHBE antisense polynucleotide agents that can be used to reduce INHBE expression in cells and subjects.[French]
Compositions et procédés utiles pour réduire l'expression du gène INHBE et pour le traitement des maladies et affections associées à l'INHBE. La présente invention concerne notamment des agents d'ARNdb de l'INHBE, des agents polynucléotidiques antisens de l'INHBE, des compositions comportant des agents d'ARNdb de l'INHBE et des compositions comportant des agents polynucléotidiques antisens de l'INHBE, qui peuvent être utilisés pour réduire l'expression de l'INHBE dans les cellules et les sujets.